| Autor: |
Zhi D; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Wang D; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Yang W; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Duan Z; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Zhu S; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Dong J; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Wang N; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Wang N; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Fei D; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Zhang Z; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Wang X; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Wang M; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China., Li H; Gansu high throughput screening and creation center for health products, School of Pharmacy, Lanzhou University, Lanzhou, P.R. China. lihy@lzu.edu.cn. |
| Abstrakt: |
Dianxianning (DXN) is a traditional Chinese formula, and has been approved in China for treating epilepsy since 1996. Here anti-Alzheimer's disease activity of DXN has been reported. DXN improved AD-like symptoms of paralysis and 5-HT sensitivity of transgenic Aβ 1-42 C. elegans. In worms, DXN significantly increased Aβ monomers and decreased the toxic Aβ oligomers, thus reducing Aβ toxicity. DXN significantly suppressed the expression of hsp-16.2 induced by juglone, and up-regulated sod-3 expression. These results indicated that DXN increased stress resistance and protected C. elegans against oxidative stress. Furthermore, DXN could significantly promote DAF-16 nuclear translocation, but it did not activate SKN-1. The inhibitory effect of DXN on the Aβ toxicity was significantly reverted by daf-16 RNAi, rather than skn-1 RNAi or hsf-1 RNAi. These results indicated that DAF-16 is at least partially required for the anti-AD effect of DXN. In conclusion, DXN improved Aβ-induced pathological characteristics partially through DAF-2/DAF-16 insulin like pathway in transgenic worms. Together with our data obtained by Morris water maze test, the results showed that DXN markedly ameliorated cognitive performance impairment induced by scopolamine in mice. All the results support that DXN is a potential drug candidate to treat Alzheimer's diseases. |
